Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
The American Journal of Managed Care1d
Emerging Therapies Shine Hope on Small Cell Lung Cancer Treatment
Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...
Nature6d
Antibody-Drug Conjugates In Cancer Therapy
Antibody-Drug Conjugate (ADC): A targeted cancer therapy that combines an antibody with a cytotoxic drug, allowing for the delivery of the drug directly to cancer cells. HER2-positive: A ...
Medscape2d
Reflections on Early Challenges and Experiences in Treating DLBCL
Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...
GlobalData on MSN2d
Innate Pharma doses first patient in Nectin-4 ADC trial
The Phase I trial will evaluate the safety and efficacy of the company’s drug which targets tumours whilst leaving normal ...
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
PharmiWeb12h
Antibody Therapy Market to Surge, Expected to Reach USD 824 Billion by 2033 at a 13.4% of CAGR
Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of ...
Medscape2d
Reflections on an Early DLBCL Case and the Evolving Treatment Landscape
Dr Suchitra Sundaram recalls a patient she treated over a decade ago and discusses how recent advances in targeted therapies have reshaped treatment strategies.
Cure Today2d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
ascopubs.org3d
A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas.
Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
manilatimes3d
Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...